Correction

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study (vol 8, e09538, 2022)

Journal

HELIYON
Volume 8, Issue 11, Pages -

Publisher

CELL PRESS
DOI: 10.1016/j.heliyon.2022.e11404

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Recommended

No Data Available
No Data Available